MarketCap
Facebook
X
Telegram
Bicycle Therapeutics plc Financial Ratios 2025-2011 | BCYC
Brief overview of Bicycle Therapeutics plc's financial ratios
Current figures are compared with the company's own five-year history for 2021–2025.
Key multiples at the end of the period are P/S 4.84x (median 29.71x), P/B 0.58x (median 2.16x). Multiples are on average 78.5% below their own medians. Shares look cheaper than their recent historical valuation.
Current measures of operating quality are ROE -35.9%, ROA -30.5%, ROCE -40.5%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
Current PEG is 0.15x; the market pays comparatively little per unit of expected growth.
The cash cycle accelerated by 61 days to 38.4 days. Less capital is tied up in operations.
Conclusion
Bicycle Therapeutics plc trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.
Annual Financial Ratios Bicycle Therapeutics plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.6 | -3.9 | -4.4 | -6.0 | -18.3 | -10.1 | -4.0 | - | - | - | - | - | - | - | - |
P/S |
4.8 | 18.5 | 29.7 | 47.0 | 104.6 | 49.4 | 8.8 | - | - | - | - | - | - | - | - |
EPS |
-3.2 | -2.9 | -5.1 | -3.8 | -2.7 | -2.7 | -2.8 | -49.8 | -48.8 | - | - | - | - | - | - |
EV (Enterprise Value) |
-169 M | -61.5 M | 500 M | 480 M | 919 M | 443 M | 138 M | 88.1 M | 53.5 M | - | - | - | - | - | - |
EBITDA per Share |
-3.47 | -3.48 | -5.15 | -3.81 | -2.56 | -2.65 | -2.29 | - | - | - | - | - | - | - | - |
EV/EBITDA |
-14.0 | -7.9 | -1.2 | - | - | - | - | - | - | - | - | ||||
PEG |
- | 0.15 | 0.09 | - | - | - | - | - | - | - | - | ||||
P/B |
0.6 | 0.8 | 2.2 | 2.5 | 3.5 | 5.4 | 1.3 | - | - | - | - | - | - | - | - |
P/CF |
-1.4 | -4.0 | -13.2 | -7.9 | -82.7 | -28.9 | -4.0 | - | - | - | - | - | - | - | - |
ROE % |
-35.90 | -21.31 | -48.71 | -41.63 | -19.30 | -53.44 | -32.84 | - | - | - | - | - | - | - | - |
ROA % |
-30.51 | -17.67 | -30.35 | -27.45 | -13.93 | -31.65 | -27.78 | - | - | - | - | - | - | - | - |
ROCE % |
-40.50 | -26.46 | -51.21 | -43.08 | -18.95 | -54.43 | -25.94 | - | - | - | - | - | - | - | - |
Current Ratio |
6.7 | 5.8 | 2.7 | 2.9 | 3.6 | 2.5 | 11.8 | - | - | - | - | - | - | - | - |
DSO |
- | - | - | 38.4 | 100.7 | 99.4 | 189.0 | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 38.4 | 100.7 | 99.4 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | 38.4 | 100.7 | 99.4 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Bicycle Therapeutics plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.14 | -0.88 | - | -0.74 | -0.77 | -0.62 | - | -1.26 | -1.41 | -1.3 | - | -0.96 | -0.9 | -0.93 | - | -0.59 | -0.74 | -0.73 | -0.83 | -0.52 | -0.67 | -0.63 | -0.25 | -0.53 | -1.4 | -7.8 | -13.19 | -17.73 | -11.85 | -6.38 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-1.23 | -0.99 | - | -0.89 | -0.87 | -0.71 | - | -1.24 | -1.37 | -1.34 | - | -0.96 | -0.9 | -0.91 | - | -0.53 | -0.71 | -0.71 | - | -0.5 | -0.66 | -0.63 | - | -0.53 | -1.03 | -3.69 | - | -13.4 | -11 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-32.24 | -24.99 | -18.13 | -30.12 | -36.00 | -50.81 | -47.42 | -57.21 | -55.01 | -44.27 | -26.75 | -35.35 | -34.15 | -38.14 | -32.60 | -50.86 | -52.89 | -52.97 | -53.44 | -39.90 | -39.46 | -37.73 | -32.84 | -18.60 | 2.59 | 20.68 | 32.97 | 23.46 | 12.45 | 5.32 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-26.55 | -20.83 | -13.72 | -21.53 | -24.25 | -29.86 | -26.30 | -33.10 | -32.08 | -28.70 | -18.79 | -24.01 | -16.43 | -24.36 | -20.37 | -31.19 | -32.27 | -31.86 | -31.65 | -24.83 | -27.15 | -28.90 | -27.78 | -31.91 | -32.73 | -29.56 | -23.66 | -15.52 | -6.10 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-37.79 | -30.19 | -21.93 | -34.14 | -38.67 | -52.92 | -48.99 | -59.27 | -57.34 | -46.52 | -27.34 | -35.71 | -33.79 | -37.19 | -31.81 | -42.99 | -45.81 | -46.82 | -36.56 | -47.56 | -47.38 | -42.77 | -23.11 | -14.00 | 6.10 | 21.77 | 16.20 | 16.20 | 7.10 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
5.1 | 6.2 | 5.8 | 6.0 | 5.8 | 2.9 | 2.6 | 2.9 | 1.9 | 2.3 | 2.9 | 3.3 | - | 3.5 | 3.6 | 2.5 | 2.7 | 2.7 | 2.5 | 2.5 | 2.5 | 2.5 | 6.5 | 6.5 | 6.5 | 6.5 | 2.8 | 2.8 | 2.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | 380.7 | 485.0 | - | - | - | 11.8 | - | - | 51.1 | 188.2 | 129.4 | 129.6 | 316.9 | 228.6 | 3.5 | 29.9 | 12.1 | 37.3 | 433.5 | 284.6 | 137.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | 380.7 | 485.0 | - | - | - | 11.8 | - | - | 51.1 | 188.2 | 129.4 | 129.6 | 316.9 | 228.6 | 3.5 | 29.9 | 12.1 | 37.3 | 433.5 | 284.6 | 137.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | 380.7 | 485.0 | - | - | - | 11.8 | - | - | 51.1 | 188.2 | 129.4 | 129.6 | 316.9 | 228.6 | 3.5 | 29.9 | 12.1 | 37.3 | 433.5 | 284.6 | 137.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Bicycle Therapeutics plc, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
